38 results
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
2022, and also due to services provided under a grant that was concluded in December 2022.
Research and development (R&D) expense: R&D expenses were … $9.0 million for the year ended December 31, 2023 and $15.9 million for the year ended December 31, 2022. The decreases in R&D expenses were primarily
8-K
EX-99.1
KA
Kineta Inc
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
was terminated in December 2022.
Research and development (R&D) expense: R&D expenses were $1.9 million for the three months ended September 30, 2023 … to $10.5 million for the nine months ended September 30, 2022. The decreases in R&D expenses were primarily due to lower activities for KVA12123
8-K
EX-99.1
KA
Kineta Inc
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
in December 2022.
Research and development (R&D) expense: R&D expenses were $2.7 million for the three months ended June 30, 2023 compared to $3.9 … ended June 30, 2022. The decreases in R&D expenses were primarily due to lower activities for KVA12123 manufacturing and clinical study start up
8-K
EX-99.1
KA
Kineta Inc
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
expenses and capital expenditure requirements into early 2025.
Research and development (R&D) expense: R&D expenses were $2.8 million for the three … months ended March 31, 2023 compared to $4.0 million for the three months ended March 31, 2022. The decrease in R&D expenses was primarily due to lower
8-K
EX-99.1
KA
Kineta Inc
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
to fund operating expenses and capital expenditure requirements for a period of at least 12 months.
Research and development expense (R&D): Research … and development expense was $15.9 million compared to $15.6 million for the prior year. The increase in R&D expense was primarily due to lower research
8-K
EX-99.3
cikp3ele6miph7
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
425
pkgun4h0s
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.1
0a0vjbhx6lvgmfe 9w
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
424B3
c6xv3 q8oci1
10 Nov 22
Prospectus supplement
4:21pm
8-K
EX-99.1
z2vlpvq6w 7vc5vid0n
4 Aug 22
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
4:51pm
425
al9a 6ku8cr5
28 Jun 22
Business combination disclosure
4:03pm
8-K
EX-99.1
byrje8rlmucuceu p4y
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
8-K
EX-99.3
rrdo q1ziafdv
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
sc9g7gx32c1zf3y
12 May 22
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
4:52pm